Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie: Powerful R&D Portfolio Backing Strong Shareholder Returns

Abbott Labs

Allergan

Bristol-Myers

And two of the three offer nice dividends, too.

3 Great Stocks That Are Still Ridiculously Cheap Right Now

Is it possible to have both growth and safety in this market?

How Safe Is AbbVie Stock and Its Dividend?

AbbVie (ABBV) closed at $81.71 in the latest trading session, marking a -0.51% move from the prior day.

AbbVie (ABBV) Stock Moves -0.51%: What You Should Know

GlaxoSmithKline

Pfizer

You'd be hard-pressed to find better dividend stocks in the market right now.

4 Dirt-Cheap Dividend Stocks to Buy as the Coronavirus Pandemic Continues

Merck

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials.

Big Pharma Short Sellers Focus on a Couple of Favorites

The time is right and the price is right to buy these big pharma stocks.

3 Top Pharma Stocks to Buy in April

AstraZeneca

Johnson & Johnson

Eli Lilly

Novartis

Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market

Without a coronavirus treatment, the medical community is experimenting with repurposed drugs. In this regard, the present crisis may benefit ABBV stock.

Ignore the Coronavirus Catalyst for ABBV Stock

Cardinal Health

Rocky Brands

Top Ranked Income Stocks to Buy for April 8th

Top Ranked Income Stocks to Buy for April 8th 2020

AbbVie stock initially fell on its $63 billion plan to buy Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?

Is AbbVie Stock A Buy Amid The Ongoing Coronavirus Pandemic?

Akamai Technologies

Ally Financial

Campbell Soup

Frontline

Gibraltar Industries

Let us examine the health of the U.S. economy this World Health Day amid the ongoing COVID-19 crisis and bring to investors notice some solid picks for a robust investment portfolio.

Analyzing Coronavirus-Hit US Economy on World Health Day: 6 Picks

Bluerock Residential Growth REIT

Coherus BioSciences

Huntington Ingalls Industries

Installed Building Products

Wall Street continues to build on a steep rebound in the previous session after lockdown strategy stabilized coronavirus outbreak in the United States and abroad.

Signs of Coronavirus Slowdown Pep Up Wall Street: 5 Winners

Healthpeak Properties Inc

Healthcare Services Group

Healthcare Trust of America

Circle The Wagons With These 4 Defensive Dividend Stocks

Innoviva

Another drug is being tested to kill the virus (if we can figure out administration on humans).

Another Drug to Fight Coronavirus & 3 Picks

Why AbbVie Stock Tanked in March

This pharma stock should be a solid pick for income-seeking investors.

Why AbbVie Is a Fantastic Dividend Stock to Buy During the Coronavirus Market Crash

BioCryst Pharmaceuticals

Gilead Sciences

Regeneron Pharmaceuticals

Roche Holding AG

Biotech Companies In The Race To Find COVID-19 Treatment

Dell Technologies

Dow Inc

FedEx

Keurig Dr Pepper Inc

Mastercard

Exxon Mobil

As the media and investors whipped up a frenzy of COVID-19 panic selling in March, some corporate insiders (such as CEOs and directors) had an entirely different take.

7 Blue-Chip Stocks You’re Selling, But Insiders Are Buying

AbbVie: Illogical 6.3% Yield

AbbVie (ABBV) stock popped on Tuesday. This is part of the global pharmaceutical giant's larger 20% surge in the last week as the market tries to mount a comeback amid the coronavirus uncertainty.

Buy this High-Yield Large Cap Pharma Stock for Income Amid Coronavirus

Automatic Data Processing

Aflac

A. O. Smith

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Chubb

Colgate-Palmolive

Dover

Ecolab

Emerson Electric

General Dynamics

Genuine Parts

McDonald's

Medtronic

McCormick

Nucor

Walgreens

In times of market turmoil, one group of stocks that investors can count on to deliver reliable income growth is the Dividend Aristocrats: an elite group of companies that have produced at least 25 consecutive years of dividend hikes.

19 Dividend Aristocrats That Have Gone on Deep Discount

Advanced Micro Devices

Now's the time to add these companies to your portfolio.

4 Stocks You'll Be Glad You Bought at These Prices

News for AbbVie Stock (ABBV)